Latest News and Press Releases

Kuros expands distribution of MagnetOs to Australia and New ZealandFirst sale of MagnetOs in Australia expected in 2020 SCHLIEREN (ZURICH), Switzerland, July 09, 2019 (GLOBE NEWSWIRE) -- Kuros...

SCHLIEREN (ZURICH), Switzerland, April 30, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) will propose the re-appointment of Clemens van Blitterswijk as Chairman of the Board of Directors,...

Financial highlights CHF 19.0 million cash & cash equivalents, trade and other receivables as at December 31, 2018Net operating costs decreased to CHF 14.3 million Operational highlights First...

Agreement with Nice & Green S.A. can be extended for an additional CHF 5 million Provides additional funds for roll-out of MagnetOs and further advancing clinical programThe Convertible Bonds are...

510(k) clearance of the TLIF cage is an important step towards progression of Fibrin-PTH product candidate KUR-113 into clinical developmentKuro’s TLIF cage will be used in combination with its...

Global partner to market an advanced bone graft supplied by KurosAgreement demonstrates interest of major orthobiologic companies in Kuros technologies SCHLIEREN (ZURICH), Switzerland, Feb. 11,...

Successfully raised CHF 16.1 million from existing and new investorsFunding secured for fibrin-PTH Phase II in spinal fusion, a huge commercial opportunityFirst sales of MagnetOs in US and Europe,...

Not for release, publication or distribution in the USA, the United Kingdom, Canada, Japan, Australia or Member States of the European Economic Area ("EEA") SCHLIEREN (ZURICH), Switzerland, Dec. 13,...

Not for release, publication or distribution in the USA, the United Kingdom, Canada, Japan, Australia or Member States of the European Economic Area ("EEA") SCHLIEREN (ZURICH), Switzerland, Dec. 12,...

US Food and Drug Administration (FDA) clearance granted for extending the use of MagnetOs Putty as a stand-alone bone graft in extremities and pelvisPaves way for commercial expansion into more...